PG
ACOR

PEAK6 Group’s Acorda Therapeutics ACOR Stock Holding History

PEAK6 Group’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-206
Closed -$586K – 5145
2018
Q1 		$586K Buy
+206
New +$617K ﹤0.01% 2434
2016
Q3 		– Sell
-23
Closed -$68.6K – 4836
2016
Q2 		$70K Buy
+23
New +$74.8K ﹤0.01% 3739
2015
Q2 		– Sell
-66
Closed -$264K – 5579
2015
Q1 		$264K Buy
+66
New +$302K ﹤0.01% 3178

Other funds holding ACOR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

PEAK6 Group's ACOR Position: Q2 2018 in Review

PEAK6 Group sold out of Acorda Therapeutics (ACOR) in Q2 2018, closing a stake of 206 shares — an estimated $586K sold.

PEAK6 Group first reported a position in ACOR in Q1 2015 and held it in 3 quarters. The position peaked at $586K in Q1 2018. 175 funds tracked by Wall St. Rank hold ACOR as of Q2 2018.

  • PEAK6 Group reported no remaining Acorda Therapeutics position as of Q2 2018 after selling out during the quarter.
  • PEAK6 Group sold 206 Acorda Therapeutics shares in Q2 2018, an estimated $586K.
  • PEAK6 Group first reported a position in Acorda Therapeutics in Q1 2015 and held it in 3 quarters.
  • PEAK6 Group's Acorda Therapeutics position peaked at $586K in Q1 2018.
  • 175 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2018.

Based on PEAK6 Group's 13F filing for Q2 2018, filed 15 Aug 2018.